Akari Therapeutics PLC (AKTX NASDAQ) stock market data APIs
$13.2374
0.27(2%)
as of June 15, 2026
Try our APIs with
free plan!
Akari Therapeutics PLC Financial Data Overview
Price chart is built with
Anychart
Akari Therapeutics, Plc, an oncology company, develops antibody-drug conjugates (ADC) for cancer-killing toxins. Its lead payload is PH1 to disrupt the function of spliceosomes and to trigger an immune response that leads to additional cancer cell killing. The company's lead product candidate is AKTX-101, a preclinical stage trop2-targeting ADC that combines PH1 with the trop2 antibody to treat solid tumor cancer types, including lung, breast, bladder, head and neck, gastric, pancreatic, colon, prostate, and others. Its payloads include PH1 is a novel payload that is a spliceosome modulator designed to disrupt RNA splicing within cancer cells. The company also develops AKTX-102, a novel bispecific ADC that utilizes PH1 as its payload to treat various solid tumor cancers. Akari Therapeutics, Plc is headquartered in Tampa, Florida.
Prev. Close
13.2374
Open
13.5069
High
13.9992
Low
12.7973
52 wk Range
3.015-49.6
Market Cap
21 096 K
P/E Ratio
0
Shares Outstanding
1 574 K
EPS
-9.7212
Beta
1.334
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Akari Therapeutics PLC data using free add-ons & libraries
Get Akari Therapeutics PLC Fundamental Data
Akari Therapeutics PLC Fundamental data includes:
- Net Revenue:
- EBITDA: -12 081 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2026-05-20
- EPS/Forecast: -2.8
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Akari Therapeutics PLC News
New
European Equities Traded in the US as American Depositary Receipts Rise in Thursday Trading
European equities traded in the US as American depositary receipts were tracking higher late Thursda PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscri...
European Equities Traded in the US as American Depositary Receipts Decline in Monday Trading
European equities traded in the US as American depositary receipts started the trading week lower la PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscri...
Top Biotech Gainers: SPRC Deal Gets Nod, CODX Rallies, OTLK, AKTX, FTRE Drawing Investor Interest
(RTTNews) - In Thursday's list of gainers, we highlight SciSparc, which received the regulatory go-ahead to acquire a stake in a private Israeli technology company, Co-Diagnostics, which extended its ...
Akari Therapeutics Highlights 1st ASCO Abstract Acceptance
By Karen Roman Akari Therapeutics, Plc (Nasdaq: AKTX) said President and CEO Abizer Gaslightwala was part of a Virtual Investor “What This Means” interview highlighting the company’s first abst...
Get Akari Therapeutics PLC fresh news feed via Financial News API
Corporate Events Calendar & News package for
$19.99/mo.
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
